



PURIFICATION, PURITY ANALYSIS, AND IMPURITY ANALYSIS SOLUTIONS

FOR PHARMACEUTICAL RESEARCH AND DEVELOPMENT

The Measure of Confidence



Agilent Technologies

REALIZE EFFECTIVE PHARMACEUTICALS

The current environment within the pharmaceutical industry—an environment shaped by patent expirations, high failure rates for new chemical entity (NCE) development, and high-profile drug recalls—provides constant pressure to increase productivity. The regulatory environment is also challenging the industry to improve its processes, requiring greater sensitivity, accuracy, and precision in quality measurements. Because of substantial overlap in the practices and technologies used, contract research and manufacturing organizations (CROs and CMOs), as well as the generic pharmaceutical industry, are faced with similar challenges.

Three key areas—purification, purity analysis, and impurity analysis—are vital to the future success of these industries, as they offer the potential both to increase productivity and to facilitate regulatory compliance.

Target Selection

Target Validation

PURIFICATION, PURITY ANALYSIS, AND IMPURITY ANALYSIS

Purification S

Flash 971

Analytical Sol

1200 Infinity
Multi-Method

Lead Identification

Lead Optimization

Pre-Clinical Development

Solutions: Flash & Preparative HPLC



Solutions for Purity Determination: LC, GC, LC/MS, CE, & SFC



Organic Impurity Profiling Solutions:



Heavy Metal Impurity Analysis: ICP-MS,



DEVELOPMENT

COMMERCIALIZATION

Clinical Development

Regulatory Approval/Manufacturing



1260 Infinity Analytical
SFC system



Poroshell 120 LC columns



OpenLAB CDS software



OpenLAB ECM software



LC, LC/MS, CE, SFC, NMR, & FTIR



6500 Series Accurate-Mass
Q-TOF LC/MS systems



6400 Series Triple
Quadrupole LC/MS systems



Poroshell 120 LC
columns




400-MR DD2 NMR
system



Cary 600 Series FTIR

& ICP-OES



OpenLAB ECM software

Residual Solvent Analysis: GC & GC/MS



7890A GC system with 7697A Headspace Sampler
and 5975C Series GC/MSD system



J&W Ultra Inert GC columns

SOLUTIONS FOR PURIFICATION, PURITY ANALYSIS, AND IMPURITY ANALYSIS

Agilent offers a wide range of advanced technologies and innovative solutions for purification, purity analysis, and impurity analysis throughout drug discovery and development. Trust Agilent to provide a suite of tools specifically designed to meet the unique challenges of your process.

A decorative graphic in the bottom left corner featuring a series of chemical structures, including benzene rings and a DNA double helix, arranged in a diagonal line across the page.

PURIFICATION

The purification of synthesized compounds is one of the most recognized and challenging bottlenecks in drug discovery. Target compound purity has a profound impact on the ability to progress from hit to viable drug candidate with minimum rework.

There has been a steady increase in the number of new chemical entities undergoing purification before any biological assays are undertaken, due primarily to the fact that valuable resources are often wasted screening impure compounds. This has led to a rise in false positives.

From the high-throughput, lower-scale (milligram) purification requirements of the medicinal chemist to the process chemist's larger-scale (grams to hundreds of grams) purification of a limited number of compounds, Agilent sets the standard in preparative liquid chromatography (LC). A broad portfolio of flexible solutions offers the performance required to meet all purification needs, from discovery to development.

Purification Solutions

Purification of routine synthetic mixtures by flash chromatography



971-FP Flash Purification System

Small-scale purification solutions for medicinal chemists



1260 Infinity Preparative-Scale LC/MS Purification System

Large-scale purification solutions for process chemists



PrepStar SD-2 System for High-Throughput Purification

PURITY ANALYSIS

Although the specific purity needs vary for drug discovery, development, and manufacturing, establishing the purity of compounds is an essential consideration across the process.

Medicinal chemists screen compound libraries in a high-throughput manner that requires rapid, generic methods. Analytical chemists in process chemistry and formulation focus on method development of reproducible and regulatory-compliant analysis methods appropriate for a limited number of target compounds. In the manufacturing phase, analytical chemists work in a fast-turnaround and highly regulated environment that requires appropriate and robust QA/QC analytical methods for a single fully characterized compound.

Agilent provides a range of liquid and gas chromatography solutions coupled with mass spectrometry (MS) systems to provide the right technology for purity analysis at each stage of the process.

Purity Analysis Solutions

Purity analysis solutions in discovery and development workflows



1200 Infinity Series Multi-Method Solution

QA/QC solutions



Regulatory Compliance
& Quality Testing Services

Purity analysis of chiral and polar compounds



1260 Infinity Analytical SFC and
7100 Capillary Electrophoresis Systems

IMPURITY ANALYSIS

A relatively new and pressing challenge for pharmaceutical scientists is the increased regulatory focus on impurities in active pharmaceutical ingredients and/or finished dosage forms. These regulations cover three main areas: organic impurities, heavy metal impurities, and residual solvents.

New regulations require disclosure of each identified degradation product, each unidentified degradation product, and total degradation products; impurities must be identified and profiled (qualified) even when present in very minor quantities.¹ There has been recent emphasis on heavy metal impurities as well, requiring much more specific instrumental methods.² The USP guidelines for residual solvents have also been updated with more comprehensive test requirements.³

Agilent is uniquely positioned to offer comprehensive solutions across all three of these impurity analysis areas, ranging from HPLC, LC/MS, CE, and SFC for organic impurities, to ICP-MS and ICP-OES for heavy metals, and GC/GC-MS for residual solvents.

¹ ICH Guidance for Industry: Q3B(R2) Impurities in New Drug Products

² USP<232> - Elemental impurities (limits) and USP<233> - Elemental impurities (procedures).

³ General Chapter <467> Residual Solvents/Organic Volatile Impurities

Impurity Analysis Solutions

Organic impurity analysis



1200 Infinity Series LC and 6500 Series Accurate-Mass Q-TOF LC/MS Systems

Heavy metal impurity analysis



7700 Series ICP-MS System

Residual solvent analysis



7890A GC System with 7697A Headspace Sampler and 5975C Series GC/MSD System

Visit www.agilent.com/lifesciences/realizepharma to see a detailed overview of the various technologies available to address the challenges faced by the pharmaceutical industry in purification, purity analysis and impurity analysis.

For more information

Learn more:

www.agilent.com/lifesciences/pharma

Buy online:

www.agilent.com/chem/store

Contact Agilent's dissolution chemists:

dissolution.hotline@agilent.com

U.S. and Canada

1-800-227-9770

agilent_inquiries@agilent.com

Europe

info_agilent@agilent.com

Asia Pacific

inquiry_lsca@agilent.com

This information is subject to change without notice.

© Agilent Technologies, Inc. 2011
Printed in USA October 26, 2011
5990-9380EN



Agilent Technologies